Published Date: 17 Feb 2023
UK: More health is associated with more cardiovascular disease (CVD) and higher triglycerides...
Read Full NewsA recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.
The newly approved inhibitor is for patients who previously received another drug of the same class.
1.
Novel biomarker has potential for predicting and treating skin cancer metastasis
2.
Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients
3.
Accurately identified high-grade prostate cancer through urine testing.
4.
Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.
5.
Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care
1.
Emerging Pathways in Hematology for Modern Medicine
2.
Beyond the Biopsy: The Evolving Landscape of Prostate Cancer Management
3.
The Pros and Cons of Steroid Therapy for ITP
4.
Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options
5.
Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation